Tessa Therapeutics Enters into Cooperative Research and Development Agreement (CRADA) with the U.S. National Cancer Institute
CRADA to support investigation of Tessa’s lead allogeneic cell therapy, TT11X, in several subtypes of…
Continue Reading-
-
Tessa Therapeutics Provides Strategic Outlook and Corporate Update for 2023
Tessa Therapeutics announced today that the company will prioritize development of its allogeneic “off-the-shelf” CD30.CAR-modified…
Continue Reading -
Tessa Therapeutics Announces Updated Safety, Efficacy and Biomarker Data from Phase 2 Trial of Autologous CD30.CAR-T Therapy (TT11) in Relapsed or Refractory Classical Hodgkin Lymphoma
Tessa Therapeutics today announced updated clinical data from the pilot stage of the ongoing Phase…
Continue Reading -
Tessa Therapeutics Announces New Clinical Data from Phase 1 Allogeneic Study Presented at 2022 Annual Meeting of American Society of Hematology (ASH)
Tessa Therapeutics today announced enhanced clinical data from an ongoing Phase 1 study (NCT04288726) of…
Continue Reading -
Tessa Therapeutics, Baylor College of Medicine Execute Agreement For Global Commercial Rights to ‘Off-the-Shelf’ CAR-T Platform
Tessa Therapeutics today announced the execution of an exclusive agreement with Baylor College of Medicine…
Continue Reading -
Tessa Therapeutics Announces Three Abstracts Highlighting Data from Autologous and Allogeneic Cell Therapy Programs Accepted for Presentation at 64th ASH Annual Meeting and Exposition
Tessa Therapeutics today announced that three abstracts reporting data from clinical trials investigating the company’s…
Continue Reading -
Tessa Therapeutics to Present at the Stifel Healthcare Conference 2022
Tessa Therapeutics today announced that Thomas Willemsen, President and CEO and Dr. Ivan D. Horak,…
Continue Reading -
Tessa Therapeutics to Participate in 2nd Annual Needham Biotech Private Company 1×1 Forum
Tessa Therapeutics today announced that Thomas Willemsen, President and CEO, Wilson W. Cheung, Chief Financial…
Continue Reading -
Tessa Therapeutics Recognized in “Most Promising Off-the-Shelf Therapies” Category at Asia-Pacific Cell & Gene Therapy Excellence Awards 2022
Tessa Therapeutics today announced that the company will host a scientific session during the SDCT-REMEDIS…
Continue Reading -
Tessa Therapeutics Appoints Thomas Willemsen as President and CEO
Tessa Therapeutics today announced the appointment of Thomas Willemsen as its President and Chief Executive…
Continue Reading